Results 241 to 250 of about 1,468,461 (396)

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody [PDF]

, 2008
Shoshana Morecki, Horst Lindhofer, Elena Yacovlev, Yael Gelfand, Peter Ruf, Shimon Slavin   +5 more
openalex   +1 more source

Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population‐based study

British Journal of Haematology, EarlyView.
In a nationwide cohort study, 873 patients with mantle cell lymphoma (MCL) were followed for a median of 7 years. During follow‐up, 28 patients developed secondary central nervous system (CNS) lymphoma (SCNSL) with a 5‐year cumulative incidence of 2.8% (95% confidence interval [CI] 1.7–3.9).
Trine Trab, Torgerð Ranadóttir, Iman Chanchiri, Ahmed Ludvigsen Al‐Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Laura Mors Haunstrup, Gabriella Cunsolo, Christian Bjørn Poulsen, Thomas Stauffer Larsen, Simon Husby, Peter Brown, Eliza A. Hawkes, Tarec C. El‐Galaly, Kirsten Grønbæk   +15 more
wiley   +1 more source

Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease

Cell Reports
Summary: Herpes simplex virus (HSV) causes lifelong infections, including oral and genital herpes. There is no vaccine, and current antivirals are only partially effective at reducing symptoms and transmission.
Chingwei V. Lee, Hector Viadiu, Apurva Kalamkar, David I. Bernstein, Andrew Pae, Xinchao Yu, Sylvia Wong, Fernando J. Bravo, Sheng Ding, Elbert Seto, Magdeleine Hung, Yu Yu, Weimei Xing, Giuseppe A. Papalia, Wei Kan, Brian Carr, Majlinda Thomas, Leah Tong, Priyanka Desai, Nadine Jarrousse, Alexandre Mercier, Meghan M. Holdorf, Simon P. Fletcher, Emma Abernathy   +23 more
doaj  

Bispecific antibodies: unleashing a new era in oncology treatment. [PDF]

Mol Cancer
Shui L, Wu D, Yang K, Sun C, Li Q, Yin R.   +5 more
europepmc   +1 more source

Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95 [PDF]

, 2008
Tanja Herrmann, Ludger Große‐Hovest, Tina Otz, Peter H. Krammer, Hans‐Georg Rammensee, Gundram Jung   +5 more
openalex   +1 more source

Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Chimeric antigen receptor (CAR) T‐cell therapy is effective for relapsed/refractory (r/r) diffuse large B‐cell lymphoma (DLBCL). However, delays between apheresis and infusion frequently occur due to limited facility capacity and prolonged bridging therapy, and the clinical impact of such delays remains uncertain.
Suguru Morimoto, Tomoyasu Jo, Toshio Kitawaki, Takashi Sakamoto, Chisaki Mizumoto, Junya Kanda, Momoko Nishikori, Kouhei Yamashita, Miki Nagao, Akifumi Takaori‐Kondo, Yasuyuki Arai   +10 more
wiley   +1 more source

Exploring T-cell bispecific antibodies in gynecologic malignancy. [PDF]

Gynecol Oncol Rep
O'Brien E, Mayer CM, Arend RC.
europepmc   +1 more source

Novel bispecific antibody causes tumor regression in patients with non-Hodgkin lymphoma [PDF]

, 2008

openalex   +1 more source

Bispecific nanobody® as a new pharmacological drug for the selective inhibition of Trypsin‐3

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Proteolytic balance is dysregulated in many diseases, with proteases playing critical roles in pathological pathways. A high level of Trypsin‐3 expression has been implicated as a significant mediator of tumour progression and metastasis, and this protease is associated with poor prognosis for patients in various cancers.
Melissa David, Anaïs Faihy, Corinne Rolland, Anissa Edir, Astrid Canivet, Laetitia Ligat, Mireille Sebbag, Nathalie Vergnolle, Aurélien Olichon, Céline Deraison   +9 more
wiley   +1 more source

Bispecific antibody toxicities

Canadian Medical Association Journal
Britto, Joanne, Mian, Hira, Davies, Gwynivere A., Balitsky, Amaris K.   +3 more
openaire   +2 more sources